Edgewise Therapeutics

Edgewise

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.

Augustine Therapeutics

This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.

Capricor

This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.

Dyne Therapeutics

The company develops oligonucleotide therapeutics to treat patients with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1.

RyCarma Therapeutics (Formerly ARMGO)

This biotech company develops small-molecule drugs to treat patients with cardiovascular and skeletal muscle diseases caused by ryanodine receptor dysfunction.

Myosin Therapeutics

This biopharmaceutical company develops small molecule therapies targeting molecular nanomotors to treat aggressive cancers and neurological disorders for patients with unmet medical needs.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.

Soufflé Therapeutics

This biotechnology company develops cell-specific oligonucleotide therapies for patients with muscular dystrophy, heart failure, and metabolic disorders.